

4. Disclosure

Tsukasa Yoshida, Osamu Takahashi, Yoko Suzuki, Erika Ota and Tetsuya Hirata declare that they have no conflicts of interest.

5. Author contributions:

Conceptualization: T. Yoshida

Data curation: T. Yoshida; Y. Suzuki

Methodology: T. Yoshida; E. Ota; O. Takahashi

Project administration: T. Yoshida; T. Hirata

Writing – original draft: T. Yoshida

Writing – review & editing: T. Yoshida; E. Ota; O. Takahashi; T. Hirata

6. References

1. Mur Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. *Hum Reprod* 2003;18(1):90–5.
2. Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. *Fertil Steril* 2014;102(2):488–95.e3.
- 3, Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. *J Clin Endocrinol Metab* 2006;91(10):3885–90.
- 4, Bonardi B, Massarotti C, Bruzzone M, et al. Efficacy and Safety of Controlled Ovarian

- Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. *Front Oncol* 2020;10:574669.
- 5, Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. *J Clin Oncol* 2005;23(19):4347–53.
 - 6, Dahhan T, Balkenende E, van Wely M, Linn S, Goddijn M. Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. *Cochrane Database Syst Rev* 2013;(11):CD010240.
 - 7, Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.
 - 8, Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev* 2019;10:ED000142.
 - 9, Kim SY, Park JE, Lee YJ, Seo H-J, Sheen S-S, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. *J Clin Epidemiol* 2013;66(4):408–14.
 - 10, Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539–58.
 - 11, Balkenende EME, Dahhan T, Beerendonk CCM, Fleischer K, Stoop D, Bos AME, et al. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. *Hum Reprod* 2022;37(8):1786–94.

- 12, Letourneau J, Juarez-Hernandez F, Wald K, Ribeiro S, Wang A, McCulloch CE, et al. Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAMoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial. *J Assist Reprod Genet* 2021;38(9):2455–63.
- 13, Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients. *Gynecol Oncol* 1999;72(2):202–7.
- 14, Arecco L, Blondeaux E, Bruzzone M, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer:(a systematic review and meta-analysis. *Hum Reprod* 2022;37(5):954–68)